Interv Akut Kardiol. 2020;19(4):229-231 | DOI: 10.36290/kar.2020.046

Sirolimus-eluting balloon catheters

Leoš Pleva1,2, Pavel Kukla1
1 Kardiovaskulární oddělení Fakultní nemocnice Ostrava
2 Lékařská fakulta Ostravské univerzity, Ostrava

Drug-eluting balloon catheters allow local delivery of an effective antiproliferative agent which reduces neointimal hyperplasia into the vessel wall. Due to its easy binding to the surface of the balloon catheter and rapid penetration into tissues, paclitaxel is mainly used as the active substance. However, sirolimus-eluting balloon catheters, similarly to sirolimus-eluting stents, could be more effective than paclitaxel.

Keywords: drug-eluting balloon catheter, sirolimus, in-stent restenosis.

Received: May 10, 2020; Revised: October 14, 2020; Accepted: October 15, 2020; Prepublished online: October 15, 2020; Published: December 3, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pleva L, Kukla P. Sirolimus-eluting balloon catheters. Interv Akut Kardiol. 2020;19(4):229-231. doi: 10.36290/kar.2020.046.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ryan TJ, Faxon DP, Gunnar RM, Kennedy JW, King SB, 3rd, Loop FD, et al. Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988; 78: 486-502. Go to original source... Go to PubMed...
    2. Mohiaddin H, Wong TDFK, Burke-Gaffney A, Bogle RG. Drug-coated balloon-only percutaneous coronary intervention for the treatment of de novo coronary artery disease: a systematic review. Cardiol Ther 2018; 7: 127-149. https://doi.org/10.1007/s40119-018-0121-2. Go to original source... Go to PubMed...
    3. Cortese B, Piraino P, Buccheri D, Alfonso F. Treatment of bifurcation lesions with drug-coated balloons: A review of currently available scientific data. Int J Cardiol 2016; 220: 589-594. Go to original source... Go to PubMed...
    4. Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, MD, Hector M. Garcia-Garcia HM, et al. Drug-coated balloon for de novo coronary artery disease. JACC state-of-the-art review. J Am Coll Cardiol 2020; 75: 1061-1073. Go to original source... Go to PubMed...
    5. Kleber FX, Mathey DG, Rittger H, Scheller B. How to use the drug eluting balloon: Recommendations by the German consensus group. EuroInterv 2011; 7: K125-128. Go to original source... Go to PubMed...
    6. Speck U, Cremers B, Kelsch B, Biedermann M, Clever YP, Schaffner S, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel? Circ Cardiovasc Interv 2012; 5: 392-400. Go to original source... Go to PubMed...
    7. Clever YP, Cremers B, Krauss B, Böhm M, Speck U, Laufs U, et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smoothmuscle cells. EuroInterv 2011; 7: K32-42. Go to original source... Go to PubMed...
    8. Scheller B, Speck U, Abramjuk C, Bernhardt U, Böhm M, Nickenig G. Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis. Circulation 2004; 110: 810-814. Go to original source... Go to PubMed...
    9. Cortese B, Bertoletti A. Paclitaxel coated balloons for coronary artery interventions: A comprehensive review of preclinical and clinical data. Int J Cardiol 2012; 161: 4-12. Go to original source... Go to PubMed...
    10. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. Final 3-year results of the SPIRIT clinical trials program. J Am Coll Cardiol Intv 2013; 6: 914-922. Go to original source... Go to PubMed...
    11. Clever YP, Peters D, Calisse J, Bettink S, Berg MC, Sperling C, et al. Novel sirolimus-coated balloon catheter in vivo evaluation in a porcine coronary model. Circ Cardiovasc Interv 2016; 9: e003543. DOI: 10.1161/CIRCINTERVENTIONS.115.003543. Go to original source... Go to PubMed...
    12. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroInterv 2013; 9: 148-156. Go to original source... Go to PubMed...
    13. Lemos PA, Farooq V, Takimura CK, Gutierrez PS, Virmani R, Kolodgie F, et al. Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroInterv 2013; 9: 148-156. Go to original source... Go to PubMed...
    14. Ali RM, Kader MAA, Ahmad WAW, Ong TK, Liew HB, Omar A, et al. Treatment of coronary drug-eluting stent restenosis by a sirolimus- or paclitaxel-coated balloon. J Am Coll Cardiol Intv 2019; 12: 558-566. Go to original source... Go to PubMed...
    15. Verheye S, Vrolix M, Kumsars I, Erglis A, Sondore D, Agostoni P, et al. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): Angiographic results and 1-year clinical outcomes. JACC Cardiovasc Interv 2017; 10(20): 2029-2037. doi:10.1016/j.jcin.2017.06.021. Go to original source... Go to PubMed...
    16. Unverdorben M, Vallbracht C, Cremers B, Heuer H, Hengstenberg C, Maikowski C, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009; 119: 2986-2994. Go to original source...
    17. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol 2012; 59: 1377-1382. Go to original source...
    18. Dani S, Shah D, Sojitra P, Parikh K, Shetty R, di Palma G, et al. A novel nanocarrier sirolimus-coated balloon for coronary interventions: 12-Month data from the Nanoluté Registry. Cardiovasc Revasc Med 2019; 20: 235-240. Go to original source... Go to PubMed...
    19. Cortese B, di Palma G, Latini RA, Elwany M, Orrego PS, Seregni RG. Immediate and short-term performance of a novel sirolimus-coated balloon during complex percutaneous coronary interventions. The FAtebenefratelli SIrolimus COated-balloon (FASICO) registry. Cardiovasc Revasc Med 2017; 18: 487-491. Go to original source... Go to PubMed...
    20. El-Mokdad R, di Palma G, Cortese B. Long-term follow-up after sirolimus-coated balloon use for coronary artery disease. Final results of the Nanolutè study. Catheter Cardiovasc Interv 2020: 1-5. DOI: 10.1002/ccd.28863. Go to original source... Go to PubMed...
    21. Stella PR, Belkacemi A, Waksman R, Stahnke S, Torguson R, von Strandmann RP, et al. The Valentines Trial: results of the first one week worldwide multicentre enrolment trial, evaluating the real world usage of the second generation DIOR paclitaxel drug-eluting balloon for in-stent restenosis treatment. EuroInterv 2011; 7: 705-710. Go to original source... Go to PubMed...
    22. Wöhrle J, Zadura M, Möbius-Winkler S, Leschke M, Opitz C, Ahmed W, et al. SeQuent Please World Wide Registry: Clinical results of SeQuent please paclitaxel-coated balloon angioplasty in a large-scale, prospective registry study. JACC 2012; 60: 1733-1738. Go to original source... Go to PubMed...

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.